There is also a suggestion that NF-κB, a known pro-inflammatory transcription factor, may be inhibited by chondroitin sulfate, hence, this agent could become a therapeutic option in AD, PD, or psoriasis (Vallières and du Souich, 2010). Here, NFKB1 is linked to psoriasis.